Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
Tremonton
Archived
•
October 23, 2025
•
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)…
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
"We build AI or anything ICST"
"Commision Art Work or Just pure Beauty."
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
Sponsored
